Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

2025 Annual and Special Meeting of Shareholders

May 27, 2025 • 10:00 am EDT

European Hematology Association Congress (EHA 2025)

Jun 12, 2025 • 5:00 pm - 6:15 pm CEST